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BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at a higher
risk of bone fractures independent of the use of antidiabetic medications.
Furthermore, antidiabetic medications could directly affect bone metabolism.
Recently, the use of dipeptidyl peptidase-4 inhibitors has been associated with a
lower rate of bone fracture. The aim of the present meta-analysis was to assess
whether patients with T2DM treated with glucagon-like peptide-1 receptor
agonists (GLP-1Ra) present a lower incidence of bone fracture compared with
patients using other antidiabetic drugs.
METHODS: A search on Medline, Embase, and http://www.clinicaltrials.gov [8],
as well as a manual search for randomized clinical trials of T2DM treated with
either a GLP-1Ra or another antidiabetic drug for a duration of ≥24 weeks was
conducted by two authors (GM, AM) independently.
RESULTS: Although 28 eligible studies were identified, only seven trials
reported the occurrence of at least a bone fracture in one arm of the trial. The
total number of fractures was 19 (13 and six with GLP-1Ra and comparator,
respectively). The pooled Mantel-Haenszel odds ratio for GLP-1Ra was 0.75 (95%
confidence interval 0.28-2.02, P = 0.569) in trials versus other antidiabetic
agents.
CONCLUSIONS: Although preliminary, our study highlighted that the use of
GLP-1Ra does not modify the risk of bone fracture in T2DM compared with the
use of other antidiabetic medications.
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